In this study, the 160 patients with NSCLC with molecular diagnostic tests by Oncomine Dx TT at the Komagome Hospital between May 2019 and July 2021 were identified as candidates for inclusion; among whom, 126 harbored of KRAS, MET, FGFR, RET, BRAF, or HER2 alterations or driver‐negative (Figure 1). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.